Sharing Individual Participant Data (IPD) within the Context of the Trial Reporting System (TRS)

PLoS Medicine

Volumn 13, Issue 1, 2016, Pages

  Zarin, Deborah A ^a   Tse, Tony ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PAROXETINE;

ARTICLE; CLINICAL ASSESSMENT; DEPRESSION; DIAGNOSTIC IMAGING; HUMAN; INDIVIDUAL PARTICIPANT DATA; INFORMATION PROCESSING; OUTCOME ASSESSMENT; PATIENT CODING; PUBLICATION; TRIAL REPORTING SYSTEM; TUMOR VOLUME; CLINICAL TRIAL (TOPIC); DRUG INDUSTRY; FACTUAL DATABASE; INFORMATION DISSEMINATION; PROCEDURES; STANDARDS;

CLINICAL TRIALS AS TOPIC; DATABASES, FACTUAL; DRUG INDUSTRY; HUMANS; INFORMATION DISSEMINATION;

EID: 84961335712     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1001946     Document Type: Article

References (24)

1. Institute of Medicine (2015) Sharing clinical trial data: maximizing benefits, minimizing risks. Washington DC: The National Academies Press.
2. Drazen JM, (2015) Sharing individual patient data from clinical trials. N Engl J Med 372: 201–202. doi: 10.1056/NEJMp1415160 25587944
3. Data Availability Policy. PLoS Med; 2016 [cited 2016 Jan 6]. http://journals.plos.org/plosmedicine/s/data-availability#loc-acceptable-data-sharing-methods.
4. Eichler HG, Abadie E, Breckenridge A, Leufkens H, Rasi G, (2012) Open clinical trial data for all? A view from regulators. PLoS Med 9: e1001202. doi: 10.1371/journal.pmed.1001202 22505851
5. Krumholz HM, Peterson ED, (2014) Open access to clinical trials data. JAMA 312: 1002–1003. doi: 10.1001/jama.2014.9647 25203080
6. Mello MM, Francer JK, Wilenzick M, Teden P, Bierer BE, et al. (2013) Preparing for responsible sharing of clinical trial data. N Engl J Med 369: 1651–1658. doi: 10.1056/NEJMhle1309073 24144394
7. Song F, Parekh S, Hooper L, Loke YK, Ryder J, et al. (2010) Dissemination and publication of research findings: an updated review of related biases. Health Technol Assess 14: iii, ix-xi, 1–193. doi: 10.3310/hta14080 20181324
8. Ebrahim S, Sohani ZN, Montoya L, Agarwal A, Thorlund K, et al. (2014) Reanalyses of randomized clinical trial data. JAMA 312: 1024–1032. doi: 10.1001/jama.2014.9646 25203082
9. Tierney JF, Vale C, Riley R, Smith CT, Stewart L, et al. (2015) Individual Participant Data (IPD) Meta-analyses of Randomised Controlled Trials: Guidance on Their Use. PLoS Med 12: e1001855. doi: 10.1371/journal.pmed.1001855 26196287
10. Tudur Smith C, Dwan K, Altman DG, Clarke M, Riley R, et al. (2014) Sharing individual participant data from clinical trials: an opinion survey regarding the establishment of a central repository. PLoS ONE 9: e97886. doi: 10.1371/journal.pone.0097886 24874700
11. Zarin DA, Tse T, (2008) Medicine. Moving toward transparency of clinical trials. Science 319: 1340–1342. doi: 10.1126/science.1153632 18323436
12. Zarin DA (2012) Presentation at IOM Workshop on Sharing Clinical Research Data. Washington DC.
13. Tse T, Zarin DA, Williams RJ, Ide NC, Gallin JI, Ognibene FP, (2012) The role and importance of clinical trial registries and results databases. In: Principles and Practice of Clinical Research 3rd ed Amsterdam: Academic Press. pp. 171–181.
14. EU Clinical Trials Register. European Medicines Agency. [cited 2016 Jan 6] https://www.clinicaltrialsregister.eu/ctr-search/search.
15. Schulz KF, Altman DG, Moher D, Group C, (2010) CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. PLoS Med 7: e1000251. doi: 10.1371/journal.pmed.1000251 20352064
16. Clinical Trial Registry Numbers in MEDLINE®/PubMed® Records. U.S. National Library of Medicine. [cited 2016 Jan 6] https://www.nlm.nih.gov/bsd/policy/clin_trials.html.
17. Zarin DA, (2013) Participant-level data and the new frontier in trial transparency. N Engl J Med 369: 468–469. doi: 10.1056/NEJMe1307268 23902488
18. Keller MB, Ryan ND, Strober M, Klein RG, Kutcher SP, et al. (2001) Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial. J Am Acad Child Adolesc Psychiatry 40: 762–772. 11437014
19. The People of the State of New York v. GlaxoSmithKline, Complaint, filed 2 June 2004. [cited 2016 Jan 6] http://news.findlaw.com/wsj/docs/glaxo/nyagglaxo60204cmp.pdf.
20. Doshi P, Dickersin K, Healy D, Vedula SS, Jefferson T, (2013) Restoring invisible and abandoned trials: a call for people to publish the findings. BMJ 346: f2865. doi: 10.1136/bmj.f2865 23766480
21. Le Noury J, Nardo JM, Healy D, Jureidini J, Raven M, et al. (2015) Restoring Study 329: efficacy and harms of paroxetine and imipramine in treatment of major depression in adolescence. BMJ 351: h4320. doi: 10.1136/bmj.h4320 26376805
22. GSK Assurance of Discontinuance, 2004. [cited 2016 Jan 6] http://www.ag.ny.gov/sites/default/files/press-releases/archived/aug26a_04_attach2.pdf.
23. Jureidini JN, McHenry LB, Mansfield PR, (2008) Clinical trials and drug promotion: Selective reporting of study 329. International Journal of Risk & Safety in Medicine 20: 76–81.
24. Leslie LK, Newman TB, Chesney PJ, Perrin JM, (2005) The Food and Drug Administration's deliberations on antidepressant use in pediatric patients. Pediatrics 116: 195–204. 15995053